星路科技開發亞洲首個港股代幣化全流程技術解決方案
復星財富控股自主孵化的全球一站式Web5(Web2+Web3)財富科技平臺「星路科技」宣佈,已與同屬復星財富控股孵化的Web3品牌──FinChain星鏈,成功聯合開發亞洲首個「港股表現掛鉤代幣」(Hong Kong Stock Performance-linked Token)全流程技術解決方案。
介紹指,此次技術解決方案由星路科技主導產品設計、合規與風控框架、跨鏈調度融合等關鍵工程,並聯合FinChain星鏈共同進行加密技術開發。FinChain星鏈則專注提升多鏈智能合約的功能性、優化跨鏈協同機制、設計高效的清算路由及流動性解決方案。
該方案率先在復星旗下復銳醫療(01696.HK)的真實業務場景中完成驗證,併成功在四大國際公鏈Ethereum、Solana、Vaulta(前EOS)、Sonic上完成多鏈部署,成爲亞洲首個具備支持多鏈運作能力的「港股表現掛鉤代幣」技術解決方案。
復銳醫療是第一家在香港聯合交易所主板上市的以色列公司,提供以能量源設備和注射填充爲核心的多元化產品組合,亦是一個致力打造以客戶爲中心的品牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.